ENTITY

Immutep (IMM AU)

23
Analysis
Health CareAustralia
Immutep Limited operates as a biotechnology company. The Company focuses on developing novel immunotherapy treatments for cancer and autoimmune disease. Immutep offers its services worldwide.
more
Refresh
bullishImmutep
22 Nov 2018 20:07Issuer-paid

Immutep - A big year ahead for efti

We expect Immutep to deliver on a number of important milestones in the year ahead. The AIPAC Phase II study of its APC activator eftilagimod alpha...

Share
bullishImmutep
21 Nov 2018 23:08Issuer-paid

Immutep - A big year ahead for efti

We expect Immutep to deliver on a number of important milestones in the year ahead. The AIPAC Phase II study of its APC activator eftilagimod alpha...

Share
bullishImmutep
27 Sep 2018 19:00Issuer-paid

Immutep - A second big pharma collaboration for efti

Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator...

Share
bullishImmutep
27 Sep 2018 15:44Issuer-paid

Immutep - A second big pharma collaboration for efti

Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator...

Share
bullishImmutep
30 Aug 2018 18:17Issuer-paid

Immutep - LAG-3 progress in-house and via partners

Immutep has reported encouraging progress from its in-house and partnered programs over the past few months. Interim data from the TACTI-mel combo...

Share
x